» Articles » PMID: 37762669

Therapeutic Effects of Curcumin Derivatives Against Obesity and Associated Metabolic Complications: A Review of In Vitro and In Vivo Studies

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Sep 28
PMID 37762669
Authors
Affiliations
Soon will be listed here.
Abstract

Obesity is a major cause of morbidity and mortality globally, increasing the risk for chronic diseases. Thus, the need to identify more effective anti-obesity agents has spurred significant interest in the health-promoting properties of natural compounds. Of these, curcumin, the most abundant and bioactive constituent of turmeric, possesses a variety of health benefits including anti-obesity effects. However, despite its anti-obesity potential, curcumin has demonstrated poor bioavailability, which limits its clinical applicability. Synthesizing curcumin derivatives, which are structurally modified analogs of curcumin, has been postulated to improve bioavailability while maintaining therapeutic efficacy. This review summarizes in vitro and in vivo studies that assessed the effects of curcumin derivatives against obesity and its associated metabolic complications. We identified eight synthetic curcumin derivatives that were shown to ameliorate obesity and metabolic dysfunction in diet-induced obese animal models, while five of these derivatives also attenuated obesity and associated metabolic complications in cell culture models. These curcumin derivatives modulated adipogenesis, lipid metabolism, insulin resistance, steatosis, lipotoxicity, inflammation, oxidative stress, endoplasmic reticulum stress, apoptosis, autophagy, fibrosis, and dyslipidemia to a greater extent than curcumin. In conclusion, the findings from this review show that compared to curcumin, synthetic curcumin derivatives present potential candidates for further development as therapeutic agents to modulate obesity and obesity-associated metabolic complications.

Citing Articles

RNA Modification in Metabolism.

Liu Y, Sun Z, Gui D, Zhao Y, Xu Y MedComm (2020). 2025; 6(3):e70135.

PMID: 40066222 PMC: 11892166. DOI: 10.1002/mco2.70135.


Exploring the role of curcumin in mitigating oxidative stress to alleviate lipid metabolism disorders.

Cheng M, Ding F, Li L, Dai C, Sun X, Xu J Front Pharmacol. 2025; 16:1517174.

PMID: 39950117 PMC: 11822302. DOI: 10.3389/fphar.2025.1517174.


The PI3K/Akt pathway: a target for curcumin's therapeutic effects.

Aliyari M, Ghoflchi S, Hashemy S, Hashemi S, Reihani A, Hosseini H J Diabetes Metab Disord. 2025; 24(1):52.

PMID: 39845908 PMC: 11748622. DOI: 10.1007/s40200-025-01563-2.


Targeting STAT3 signaling pathway by curcumin and its analogues for breast cancer: A narrative review.

Golmohammadi M, Zamanian M, Al-Ani A, Jabbar T, Kareem A, Aghaei Z Animal Model Exp Med. 2024; 7(6):853-867.

PMID: 39219410 PMC: 11680487. DOI: 10.1002/ame2.12491.


Obesity-Associated Colorectal Cancer.

Gonzalez-Gutierrez L, Motino O, Barriuso D, de la Puente-Aldea J, Alvarez-Frutos L, Kroemer G Int J Mol Sci. 2024; 25(16).

PMID: 39201522 PMC: 11354800. DOI: 10.3390/ijms25168836.


References
1.
Pan M, Huang T, Lin J . Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos. 1999; 27(4):486-94. View

2.
Mokgalaboni K, Ntamo Y, Ziqubu K, Nyambuya T, Nkambule B, Mazibuko-Mbeje S . Curcumin supplementation improves biomarkers of oxidative stress and inflammation in conditions of obesity, type 2 diabetes and NAFLD: updating the status of clinical evidence. Food Funct. 2021; 12(24):12235-12249. DOI: 10.1039/d1fo02696h. View

3.
Priyadarsini K . The chemistry of curcumin: from extraction to therapeutic agent. Molecules. 2014; 19(12):20091-112. PMC: 6270789. DOI: 10.3390/molecules191220091. View

4.
Selvam C, Jachak S, Thilagavathi R, Chakraborti A . Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. Bioorg Med Chem Lett. 2005; 15(7):1793-7. DOI: 10.1016/j.bmcl.2005.02.039. View

5.
Lapchak P, McKim Jr J . CeeTox™ Analysis of CNB-001 a Novel Curcumin-Based Neurotrophic/Neuroprotective Lead Compound to Treat Stroke: Comparison with NXY-059 and Radicut. Transl Stroke Res. 2011; 2(1):51-9. PMC: 3074116. DOI: 10.1007/s12975-010-0034-4. View